PhRMA releases new report on challenges to developing new hepatitis C treatments

19 December 2014

The Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report examining the scientific challenges on the road to developing new hepatitis C treatments.

The report, Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones, found that between 1998 and 2014, 77 investigational medicines failed in clinical trials, and that 12 medicines were approved in the same time period.

The ability to learn from the setbacks along the development pathway informed innovation in treatment, and the evolution of treatment from interferon-based therapy to direct-acting antivirals has been a significant response to these challenges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >